Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

Empagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated. METHODS: Patients with class II through IV heart failure and a left ventricular ejection fraction...

Descripción completa

Detalles Bibliográficos
Autores principales: Filippatos, Gerasimos, Butler, Javed, Farmakis, Dimitrios, Zannad, Faiez, Ofstad, Anne Pernille, Ferreira, João Pedro, Green, Jennifer B., Rosenstock, Julio, Schnaidt, Sven, Brueckmann, Martina, Pocock, Stuart J., Packer, Milton, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422757/
https://www.ncbi.nlm.nih.gov/pubmed/35762322
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422757/
https://www.ncbi.nlm.nih.gov/pubmed/35762322
http://dx.doi.org/10.1161/CIRCULATIONAHA.122.059785

Ejemplares similares